<?xml version="1.0" encoding="UTF-8"?>
<xml>
<records>
<record>
  <contributors>
    <authors>
      <author>Oken, Adam</author>
      <author>Krishnamurthy, Ipsita</author>
      <author>Lisi, Nic</author>
      <author>Godsey, Michael H.</author>
      <author>Mansoor, Steven E.</author>
    </authors>
  </contributors>
  <titles>
    <title>Molecular pharmacology of P2X7 receptor ligands visualized by Cryo-EM</title>
    <translated-title/>
    <tertiary-title/>
  </titles>
  <periodical>
    <full-title/>
  </periodical>
  <alt-periodical>
    <full-title/>
    <abbr-1/>
  </alt-periodical>
  <pages/>
  <section/>
  <volume/>
  <number/>
  <keywords>
    <keyword>structural biology</keyword>
    <keyword>cryo-em</keyword>
    <keyword>p2x7</keyword>
    <keyword>p2xrs</keyword>
    <keyword>Ion Channels</keyword>
    <keyword>Receptors, Purinergic</keyword>
  </keywords>
  <dates>
    <year>2022</year>
    <pub-dates>
      <date>2022</date>
    </pub-dates>
  </dates>
  <abstract>Extracellular ATP is a critical signaling molecule that is found in a wide range of concentrations across cellular environments. The family of nonselective cation channels that recognize extracellular ATP, termed P2X receptors (P2XRs), is composed of seven sub-types (P2X1-P2X7) that assemble as functional homo-trimeric and hetero-trimeric ion channels. The therapeutic potential of P2XRs is an emerging area of research, as overactive P2XRs have been shown to play pathophysiological roles in neuro-inflammation, vascular inflammation, and cell division. Although there are currently no FDA-approved drugs targeting P2XRs, structure-based drug design can provide unique and insightful details into the intricacies of each receptor to facilitate sub-type selective ligands. Here, we highlight potential therapeutically targetable sites in the P2XR family and how single-particle cryogenic electron microscopy (cryo-EM) can be used to advance drug discovery, focusing on two cryo-EM structures; the endogenous agonist ATP bound to P2X7 and the noncompetitive antagonist JNJ-47965567 bound to P2X7.</abstract>
  <pub-location/>
  <publisher>Oregon Health and Science University</publisher>
  <issn/>
  <isbn/>
  <custom3/>
  <custom7/>
  <notes/>
  <work-type>Abstract</work-type>
  <electronic-resource-num>10.6083/q811kk38w</electronic-resource-num>
  <urls>
    <related-urls>
      <url>https://digitalcollections.ohsu.edu/record/9572/files/Oken-Adam-OHSU-ResearchWeek-2022.pdf</url>
    </related-urls>
  </urls>
  <language/>
</record>

</records>
</xml>